Amplimune™ Now Available in Canada

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

Amplimune® Receives Regulatory Approval in New Zealand

NovaVive's immunotherapy for calf scours - Amplimune® - has received approval for sale in New Zealand by Agricultural Compounds and Veterinary Medicines (ACVM). NovaVive has appointed Agilis Vet Ltd as its NZ distributor.

learn more

NovaVive Seeking to Enhance Quality of Life of Dogs with Cancer

Immunocidin is being evaluated in a clinical study as a palliative therapy for dogs with malignant cancer. The goal is to increase the dogs' comfort and maintain or improve the quality and duration of their remaining life.

learn more

Results from a Study with Immunocidin® Equine for Sarcoid Tumors Being Published in the Journal of Equine Veterinary Science

An Iowa State University study concluded that Immunocidin Equine was effective in 52.9% of the cases enrolled (that had a known outcome) after 2-5 injections. The treatment was deemed safe, with swelling the only side effect.

learn more

Follow NovaVive on Social Media.